Dose-dependent mutation rates determine optimum erlotinib dosing strategies for EGFR mutant non-small cell lung cancer patients

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Liu, Lin L ^a,b   Li, Fei ^a   Pao, William ^c   Michor, Franziska ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; HUMAN; LOADING DRUG DOSE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; MUTATION RATE; NON SMALL CELL LUNG CANCER; POINT MUTATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE RESPONSE; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; THEORETICAL MODEL;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MODELS, THEORETICAL; MUTATION; MUTATION RATE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84951188168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141665     Document Type: Article

References (52)

1. Allgayer H, Fulda S. An introduction to molecular targeted therapy of cancer. Adv Med Sci. 2008; 53 (2):130-138. PMID: 18650147
2. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008 Feb; 77(3):311-319. PMID: 18297955
3. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008 Oct; 13(10):1084-1096. doi: 10.1634/theoncologist.2008-0120 PMID: 18838439
4. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977; 61:1307-1317. PMID: 589597
5. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986; 70:163-169. PMID: 3510732
6. Citron ML, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21(11):1431-1439. PMID: 12668651
7. Dibrov B, Zhabotinsky A, Neyfakh Y, Orlova M, Churikova L. Optimal Scheduling for Cell Synchronization by Cycle-Phase-Specific Blockers. Math Biosci. 1983; 66:167-185. doi: 10.1016/0025-5564(83) 90087-1
8. Agur Z. The effect of drug schedule on responsiveness to chemotherapy. Ann Acad New York Sci. 1986; 504:274-277. doi: 10.1111/j.1749-6632.1987.tb48738.x
9. Panetta JC. A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment. Bull Math Biol. 1996; 58:425-447. doi: 10.1007/BF02460591 PMID: 8688836
10. Costa MI, Boldrini JL, Bassanezi RC. Drug kinetics and drug resistance in optimal chemotherapy. Math Biosci. 1995; 125:191-209. doi: 10.1016/0025-5564(94)00027-W PMID: 7881194
11. Hahnfeldt P, Folkman J, Hlatky L. Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis. J Theor Biol. 2003; 220:545-554. doi: 10. 1006/jtbi.2003.3162 PMID: 12623285
12. Gardner S, Fernandes M. New tools for cancer chemotherapy: computational assistance for tailoring treatments. Mol Cancer Therapeutics. 2003; 2:1079-1084.
13. Swan GW. Role of optimal control in chemotherapy. Math Biosci. 1990; 101(2):237-284. doi: 10.1016/0025-5564(90)90021-P PMID: 2134485
14. Martin R, Teo KL. Optimal control of drug administration in cancer chemotherapy. World Scientific Publishin; 1994.
15. Coldman A, Goldie J. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol. 1986; 48(3/4):279-292. doi: 10.1007/BF02459682 PMID: 3828558
16. Coldman A, Murray J. Optimal control for a stochastic model of cancer chemotherapy. Math Biosciences. 2000; 168:187-200. doi: 10.1016/S0025-5564(00)00045-6
17. Day RS. Treatment sequencing, asymmetry, and uncertainty: Protocol strategies for combination chemotherapy. Cancer Research. 1986; 46:3876-3885. PMID: 3731062
18. Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proc Roy Soc Lond B. 2003;270:2572-2578.
19. Komarova NL, Wodarz D. Drug resistance in cancer: Principles of emergence and prevention. PNAS. 2005; 102:9714-9719. doi: 10.1073/pnas.0501870102 PMID: 15980154
20. Komarova NL. Stochastic modeling of drug resistance in cancer. J Theor Biol. 2006; 239:351-366. doi: 10.1016/j.jtbi.2005.08.003 PMID: 16194548
21. Iwasa Y, Nowak MA, Michor F. Evolution of resistance during clonal expansion. Genetics. 2006; 172:2557-2566. doi: 10.1534/genetics.105.049791 PMID: 16636113
22. Haeno H, Y YI, Michor F. The Evolution of Two Mutations During Clonal Expansion. Genetics. 2007; 177:2209-2221. doi: 10.1534/genetics.107.078915 PMID: 18073428
23. Comen E, Morris PG, Norton L. Translating Mathematical Modeling of Tumor Growth Patterns into Novel Therapeutic Approaches for Breast Cancer. Journal of mammary gland biology and neoplasia. 2012; 17(3-4):241-249. doi: 10.1007/s10911-012-9267-z PMID: 23011603
24. De Pillis LG, Radunskaya A. A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. Computational and Mathematical Methods in Medicine. 2001; 3(2):79-100.
25. de Pillis LG, Radunskaya AE, Wiseman CL. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Research. 2005; 65(17):7950-7958. PMID: 16140967
26. Costa M, Boldrini J, Bassanezi R. Drug kinetics and drug resistance in optimal chemotherapy. Mathematical biosciences. 1995; 125(2):191-209. doi: 10.1016/0025-5564(94)00027-W PMID: 7881194
27. Kohandel M, Sivaloganathan S, Oza A. Mathematical modeling of ovarian cancer treatments: sequencing of surgery and chemotherapy. Journal of theoretical biology. 2006; 242(1):62-68. doi: 10.1016/j.jtbi. 2006.02.001 PMID: 16580022
28. Gardner SN. Modeling multi-drug chemotherapy: tailoring treatment to individuals. Journal of theoretical biology. 2002; 214(2):181-207. doi: 10.1006/jtbi.2001.2459 PMID: 11812172
29. Komarova NL, Wodarz D. Effect of cellular quiescence on the success of targeted CML therapy. PLoS One. 2007; 2(10):e990. doi: 10.1371/journal.pone.0000990 PMID: 17912367
30. Komarova NL, Wodarz D. Stochastic modeling of cellular colonies with quiescence: an application to drug resistance in cancer. Theoretical population biology. 2007; 72(4):523-538. doi: 10.1016/j.tpb. 2007.08.003 PMID: 17915274
31. Foo J, Michor F. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies. PLoS Comput Biol. 2009 Nov; 5(11):e1000557. doi: 10.1371/journal.pcbi. 1000557 PMID: 19893626
32. Foo J, Michor F. Evolution of resistance to anti-cancer therapy during general dosing schedules. J Theor Biol. 2010 Mar; 263(2):179-88. doi: 10.1016/j.jtbi.2009.11.022 PMID: 20004211
33. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Science translational medicine. 2011; 3(90):90ra59. doi: 10.1126/scitranslmed.3002356 PMID: 21734175
34. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000; 5(5):415-418. doi: 10.1023/A:1009616228304 PMID: 11256882
35. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006; 108(1):319-327. doi: 10.1182/blood-2005-07-2815 PMID: 16527898
36. Davis W, Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. Journal of Pharmacology and Experimental Therapeutics. 2001; 296(1):1-6. PMID: 11123355
37. Ghibelli L, Coppola S, Rotilio G, Lafavia E, Maresca V, Ciriolo M. Non-oxidative loss of glutathione in apoptosis via GSH extrusion. Biochemical and biophysical research communications. 1995; 216 (1):313-320. doi: 10.1006/bbrc.1995.2626 PMID: 7488106
38. Hug H, Strand S, Grambihler A, Galle J, Hack V, Stremmel W, et al. Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells. Journal of Biological Chemistry. 1997; 272(45):28191-28193. doi: 10.1074/jbc.272.45.28191 PMID: 9353266
39. England K, 'Driscoll CO, Cotter TG. ROS and protein oxidation in early stages of cytotoxic drug induced apoptosis. Free Radical Research. 2006; 40(11):1124-1137. doi: 10.1080/10715760600838209 PMID: 17050166
40. Tortora G. Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr. 2011; 2011 (43):95-8. doi: 10.1093/jncimonographs/lgr026 PMID: 22043051
41. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature. 2012 Jun; 486(7404):537-40. doi: 10.1038/nature11219 PMID: 22722843
42. Lewis PA, Shedler GS. Simulation of nonhomogeneous Poisson processes by thinning. Naval Research Logistics Quarterly. 1979; 26(3):403-413. doi: 10.1002/nav.3800260304
43. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2013. Available from: http://www.R-project.org/
44. Dempsey JL, Seshadri RS, Morley AA. Increased mutation frequency following treatment with cancer chemotherapy. Cancer research. 1985; 45(6):2873-2877. PMID: 3986814
45. Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003; 102(2):659-661. doi: 10.1182/blood-2002-06-1756 PMID: 12663457
46. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell. 2002; 2(2):117-125. PMID: 12204532
47. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Laï JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood. 2002; 100(3):1014-1018. doi: 10.1182/blood.V100.3.1014 PMID: 12130516
48. Roche-Lestienne C, Laï JL, Darré S, Facon T, Preudhomme C. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. New England Journal of Medicine. 2003; 348(22):2265-2266. doi: 10.1056/NEJMc035089 PMID: 12773665
49. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC. Cancer cell. 2010; 17(1):77-88. doi: 10.1016/j. ccr.2009.11.022 PMID: 20129249
50. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. New England Journal of Medicine. 2008; 359(4):366-377. doi: 10.1056/NEJMoa0800668 PMID: 18596266
51. Jia P, Jin H, Catherine B, Xia J, Ohashi K, Liu L, et al. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and-resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome research. 2013;. doi: 10.1101/gr.152322.112 PMID: 23733853
52. DeVita VT. Single agent versus combination chemotherapy. CA: A Cancer Journal for Clinicians. 1975; 25(3):152-158.